Drug Metabolism and Disposition Fast Forward
First published on July 10, 2008; DOI: 10.1124/dmd.108.020354
0090-9556/08/3610-2024-2029$20.00
DMD 36:2024-2029, 2008
Pharmacokinetics of the Novel Nicotinic Receptor Antagonist N,N'-Dodecane-1,12-diyl-bis-3-picolinium Dibromide in the Rat
Zaineb A. Fadhel Albayati,
Linda P. Dwoskin, and
Peter A. Crooks
Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky
(Received April 19, 2008;
Accepted July 8, 2008)
 |
Abstract
|
|---|
Plasma and brain concentrations of the nicotinic acetylcholine receptor antagonist and blood-brain barrier choline transporter substrate, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), were analyzed by liquid β-scintillation spectrometry after administration of [14CH3]bPiDDB to male Sprague-Dawley rats. Plasma concentrations of [14CH3]bPiDDB were determined at 10 time points over 3 h. Absolute plasma bioavailabilities (1, 3, and 5.6 mg/kg s.c.) were 80.3, 68.2, and 103.7%, respectively. bPiDDB (1, 3, and 5.6 mg/kg) gave Cmax values of 0.13, 0.33, and 0.43 µg/ml, respectively, Tmax values of 5.0, 6.7, and 8.8 min, respectively, and t1/2 values of 76.0, 54.6, and 41.7 min, respectively. Mean area under the plasma concentration versus time curve from time zero to infinity (micrograms per minute per milliliter) and mean Cmax (µg/ml) values were dose-dependent (r2 = 0.9361 and 0.7968, respectively) over the dose range studied. No metabolism of [14CH3]bPiDDB was detected with any dose of bPiDDB administered. Only moderate protein binding (63–65% in plasma and 59–62% in brain supernatant) was observed, which was reversible. Brain concentrations and brain/plasma ratios of bPiDDB after a single 5.6 mg/kg s.c. dose over 5 to 60 min ranged from 0.09 to 0.33 µg/g brain tissue and were maximal at 10 min after injection, representing approximately 0.6% of the administered dose. Brain/blood ratio (0.18 at 5 min to 0.51 at 60 min after injection) was observed, indicating that clearance from brain is slower than clearance from plasma. The results show that bPiDDB is distributed rapidly from the site of injection into plasma, affords good plasma concentrations, and appears to reach brain tissues via facilitated transport by the blood-brain barrier choline transporter to afford therapeutically relevant concentrations in rat brain.
Habitual tobacco use is a major contributing factor to many preventable health problems, including lung cancer, emphysema, and cardiovascular disease. The Centers for Disease Control and Prevention describes tobacco use as the single most important preventable risk to human health and an important cause of premature death worldwide (Chen and Mannino, 1999
; Mannino and Braman, 2007). Nicotine replacement therapies (e.g., nicotine gum, transdermal patch, nasal spray, and inhaler) have been used to relieve craving and withdrawal symptoms and result in diminished exposure of the smoker to toxic components of tobacco smoke. Several non-nicotine therapies have been used as treatments for nicotine addiction, including bupropion, an antidepressant medication with neuronal nicotinic receptor (nAChR) antagonist properties (Dwoskin et al., 2006), and varenicline, a partial agonist at 
4β2 nAChRs and full agonist at 7 nAChRs (Coe et al., 2005; Mihalak et al., 2006). Mecamylamine, a nonselective antagonist at both central and peripheral nAChRs, has been developed for use as a tobacco cessation agent, but its clinical use has been precluded by peripheral side effects, such as dry mouth and constipation (Lundahl et al., 2000). Despite some success of the currently available pharmacotherapies, relapse rates continue to be high, indicating that novel medications are still needed.
Our research group has recently synthesized a library of bis-azaaromatic quaternary ammonium analogs that act as central nAChR antagonists (Dwoskin and Crooks, 2001; Ayers et al., 2002; Zheng et al., 2007). N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) (Fig. 1) is a novel polar bis-quaternary ammonium salt currently being developed as a nAChR antagonist that inhibits nAChRs mediating nicotine-evoked dopamine release. bPiDDB potently inhibits nicotine-evoked dopamine release from superfused rat striatal slices with an IC50 value of 5 nM. In addition, bPiDDB selectively decreases the reinforcing effect of nicotine (Dwoskin et al., 2004, 2007; Neugebauer et al., 2006). Recently, in vivo microdialysis studies have demonstrated that bPiDDB dose dependently reduces nicotine-evoked extracellular dopamine release in rat nucleus accumbens (Rahman et al., 2007). Because bPiDDB is a polar, cationic molecule, it might be expected not to penetrate the blood-brain barrier and bind to central nAChRs. However, recent studies have shown that bPiDDB is an excellent substrate for the blood-brain barrier choline transporter (Allen et al., 2003; Geldenhuys et al., 2005; Lockman et al., 2008) and accesses brain via facilitated transport.
View larger version (8K):
[in this window]
[in a new window]
|
FIG. 1. Chemical structure of N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide. *, location of the 14C radiolabel.
|
|
The objective of the current investigation was to determine the plasma pharmacokinetic parameters, blood-brain barrier permeation, and protein binding of [14CH3]bPiDDB in rats after s.c. administration, as a first step toward understanding the overall pharmacokinetic profile of this novel nAChR antagonist. The s.c. route was chosen in the current pharmacokinetic studies, because this route of administration was used in the behavioral studies, which will enable behaviorally relevant brain concentrations of bPiDDB to be determined.
|
Materials and Methods
|
|---|
Chemicals. bPiDDB was prepared using the method of Ayers et al. (2002). [14CH3]bPiDDB (specific activity 50 mCi/mmol) was obtained from Moravek Biochemicals (Brea, CA) and synthesized via 3-methylation of 4-chloropyridine with lithium diisopropylamide and 14CH3I, followed by hydrogenolysis with Pd/C-KOAc as catalyst to remove the 4-chloro group. Reaction of the resulting [14CH3]3-picoline with 1,12-dibromododecane produced [14CH3]-bPiDDB; radiochemical purity was >98% (Ayers et al., 2002). The chemicals used in this study were of HPLC grade or equivalent quality. Acetonitrile, formic acid, ammonium formate, potassium chloride, and Bio-Safe NA scintillation cocktail were obtained from Thermo Fisher Scientific (Pittsburgh, PA). Heparin sodium injection, 10,000 USP units/ml, was purchased from Baxter Healthcare Corporation (Deerfield, IL). Nembutal sodium (pentobarbital sodium injection, USP) was obtained from Abbott Laboratories (North Chicago, IL).
Animals. All procedures involving animals were performed in compliance with the guidelines of the University of Kentucky Institutional Animal Care and Use Committee established by the National Institutes of Health's Guide for the Care and Use of Laboratory Animals (1996). Male Sprague-Dawley rats (200–250 g) were obtained from Harlan (Indianapolis, IN) and housed two per cage with ad libitum access to food and water in the Division of Laboratory Animal Resources at the University of Kentucky College of Pharmacy. Body weights at the time of dosing were 290 to 310 g. Rats were anesthetized with pentobarbital (40 mg/kg i.p.) and surgically implanted with jugular and femoral vein cannulas for i.v. drug dosing and blood sampling, respectively. bPiDDB was injected s.c. in the back of the animal between the shoulder blades. For the first 3 to 4 days after surgery, the rats were observed for signs of infection at the surgical sites, yellowing of hair and hair texture, presence of blood around the eyes or nose, indications of loss of appetite, and decreased or absent fecal activity before the start of s.c. or i.v. dosing. The i.v. and s.c. dosing was performed in a parallel design.
Plasma Pharmacokinetics. Solutions of bPiDDB containing a tracer amount (50 µCi) of [14CH3]bPiDDB were prepared in fresh phosphate-buffered saline and filtered through a 0.2-µm filter. Groups of rats (n = 3–5) were then injected with either 1, 3, or 5.6 mg/kg s.c. or 1 mg/kg i.v. [14CH3]bPiDDB via the jugular vein. Doses and route of administration were chosen on the basis of recent studies evaluating the effect of bPiDDB on behavioral activity in nicotine-dependent rats (Neugebauer et al., 2006). Blood samples (0.15 ml) were obtained at 0, 1, 5, 10, 15, 20, 30, 45, 60, 120, and 180 min after injection of each dose. The withdrawn blood was replaced with heparinized saline (0.15 ml). Blood samples were centrifuged at 1200g for 15 min, and the plasma was separated. Plasma samples (50 µl) were mixed with 3.5 ml of scintillation cocktail (Bio-Safe NA) and analyzed directly for the presence of [14CH3]-bPiDDB by β-scintillation spectrometric analysis (Tri-Carb 2200 TR liquid scintillation spectrometer; PerkinElmer Life and Analytical Sciences, Shelton, CT).
Pharmacokinetic Analysis. The plasma pharmacokinetic parameters for bPiDDB in the rat were determined after both s.c. and i.v. administration. Data were analyzed with a standard noncompartmental model using the program WinNonlin Professional (version 4.1; Pharsight Corporation, Mountain View, CA). Both Cmax and Tmax were determined. The AUC0–t for the plasma concentration-time profile was determined using the linear-trapezoidal method (Whittaker and Robinson, 1967). AUC0–
was calculated as AUC0–t + Ct/k, where Ct is the last measurable concentration of drug. The terminal half-life (t1/2) of bPiDDB was calculated by dividing 0.693 by the terminal rate constant (k) obtained from the fitted concentration-time data. The area under the first moment curve (AUMC) for bPiDDB was determined using the linear-trapezoidal method with extrapolation to infinite time (Clast · tlast/k + Clast/k2). Systemic clearance (CL) after the i.v. dose of bPiDDB was determined from eq. 1:
 | (1) |
Volume of distribution at steady state (Vss) for the i.v. dose of bPiDDB was determined from eq. 2:
 | (2) |
Systemic bioavailability after s.c. administration of bPiDDB (F) was determined from eq. 3:
 | (3) |
where AUCs. c., AUCi. v., Doses. c., and Dosei. v. represent the AUC0– and corresponding dose for the s.c. and i.v. injections, respectively.
Brain Uptake Studies. Studies were performed to determine the amount of bPiDDB in brain after an s.c. dose of 5.6 mg/kg. A solution (0.25 ml) of bPiDDB containing a tracer amount (50 µCi) of [14CH3]bPiDDB and a total dose of 5.6 mg/kg bPiDDB was prepared in fresh phosphate-buffered saline and filtered through a 0.2-µm filter. This dose was chosen as it has been shown to produce a robust behavioral effect in a rat model of nicotine dependence (M. T. Bardo, L. P. Dwoskin, and P. A. Crooks, unpublished results). Non-catheterized male Sprague-Dawley rats (250–270 g) were assigned randomly to one of six time points (n = 4 per group). Individual rats were euthanized at 0, 1, 5, 10, 15, 20, and 60 min after s.c. administration of bPiDDB. The brain was quickly removed, cleaned of surrounding tissue and veins, washed, weighed, and homogenized (3 volumes of 1.15% KCl/g brain tissue) for 2 min in a tissue homogenizer (Bio-Homogenizer M133/1281-0; Biospec Products, Inc., Barlesville, OK). Brain homogenate (4 ml) was mixed with an equal volume of a solution consisting of a 40:60 mixture of acetonitrile-0.1% formic acid, pH 2.3. The resulting mixture was then mixed with an equal volume of acetonitrile and centrifuged at 1200g and 37°C for 5 min. The supernatant was separated and evaporated to dryness under a stream of nitrogen. The residue was reconstituted in 0.2 ml of HPLC mobile phase consisting of 40:60 acetonitrile-2 mM ammonium formate, pH 2.3. After decapitation, blood from the trunk of each rat at the time of euthanasia was also collected and centrifuged at 1200g and 37°C for 5 min to obtain matching brain/plasma samples. The plasma samples (1 ml) were extracted with 6 volumes of acetonitrile and centrifuged at 1200 g for 15 min at 37°C. The supernatant was separated and evaporated to dryness under a stream of nitrogen, and the resulting residue was dissolved in 0.2 ml of 40:60 acetonitrile-2 mM ammonium formate, pH 2.3. To determine [14C]bPiDDB and its metabolites, plasma and brain homogenate samples containing [14C]bPiDDB were each mixed with an authentic sample of bPiDDB to produce a final concentration of 0.01 mg/ml, which acted as a UV-absorbing standard, and an aliquot of each final mixture (20 µl) was injected onto a C18 Alltima column (5 µm, 150 x 3.2 mm; Alltech Associates, Deerfield, IL). The mobile phase consisted of 2 mM ammonium formate-acetonitrile (60:40), adjusted to pH 2.3 with 0.1% formic acid and containing 0.1% heptafluorobutyric acid; the flow rate was 0.4 ml/min. An Agilent 1100 series HPLC analytical system interphased to an L-4000 UV detector, an L-6000 intelligent pump, an AS-2000 autosampler, and a D-2500 chromatointegrator (Hitachi, Tokyo, Japan) was used.
Fractions (
70 µl/10 s) eluting from the HPLC column were collected over 60 min for determination of 14C radiolabel in the column effluent. A volume of 20 µl identical to that injected onto the HPLC column was added to 3.0 ml of scintillation cocktail and analyzed directly by β-scintillation spectrometry to determine recovery of 14C radiolabel from the HPLC column. UV detection of a bPiDDB standard in plasma and brain homogenate samples was monitored continuously at 260 nm to determine the time of appearance of [14CH3]-bPiDDB in the column effluent.
View larger version (16K):
[in this window]
[in a new window]
|
FIG. 2. High-pressure liquid radiochromatogram of plasma from a rat that had been dosed s.c. with [14CH3]bPiDDB. An authentic UV-absorbing standard of bPiDDB was coinjected with the plasma sample. Top chromatogram, radioactivity in column effluents from a plasma sample of a rat that had been dosed s.c. with [14CH3]bPiDDB determined by β-scintillation spectrometry. Bottom chromatogram, UV detection of coinjected standard at 260 nm. Chromatographic conditions for A and B were as described in the text.
|
|
Plasma Protein and Brain Protein Binding of bPiDDB in the Rat. The ability of bPiDDB to bind to plasma and brain proteins was determined using a modification of the ultrafiltration method of Cheng et al. (2004). A Centrifree Micropartition device (Amicon; Millipore Corporation, Beverly, MA) was used for separating unbound bPiDDB from bound bPiDDB. bPiDDB was dissolved in water and added to either rat plasma (1 ml) or whole brain supernatant (1 ml) to give concentrations of 0.04 and 0.1 mg/ml. The spiked plasma or brain supernatant was incubated for 15 min at 37°C and an aliquot part (50 µl) was analyzed by HPLC to determine bPiDDB concentration, as described previously. The ultrafiltrate was obtained by centrifugation at 1000g and 37°C for 10 min. The concentration of unbound bPiDDB in the filtrate was determined by HPLC analysis and UV detection at 260 nm, as described previously. Chromatography was performed on a C18 Alltima column (3.2 x 150 mm, 5 µm; Alltech Associates). The mobile phase consisted of 2 mM ammonium formate-acetonitrile (60:40), adjusted to pH 2.3 with 0.1% formic acid containing 0.1% heptafluorobutyric acid; the flow rate was 0.4 ml/min. A calibration curve was constructed from the bPiDDB peak area versus concentration (r2 = 0.998) and was used to quantitate the amount of bPiDDB in the ultrafiltrate. The HPLC method was validated over the concentration range 1 to 200 µg /ml. The limit of quantitation was established at 1 µg/ml. The percentage of free fraction of bPiDDB was calculated from eq. 4:
 | (4) |
In separate experiments to determine whether the observed binding of bPiDDB to plasma and brain protein was reversible or irreversible, radiolabeled [14CH3]bPiDDB was used as a tracer compound. Plasma or brain supernatants containing [14CH3]bPiDDB (concentrations of 1, 1.5, 15, 50, 100, 200, 250, and 400 µg/ml in both cases) were used. After incubation for 15 min at 37°C, aliquot parts (50 µl) were taken, and radioactivity was determined by liquid scintillation spectrometry. The spiked plasma or brain sample was added to the sample reservoir of a Centrifree Micropartition device to separate unbound bPiDDB from bound bPiDDB. Samples were centrifuged for 10 min at 1000g and 37°C, and radioactivity in the ultrafiltrate was determined by liquid scintillation spectrometry (Musick et al., 2008). The concentration of bound bPiDDB versus unbound bPiDDB was then plotted to give the binding curve.
Statistics. Results were first analyzed by a one-way analysis of variance. Individual differences between means were determined using Tukey's post hoc test. P < 0.05 was considered statistically significant. Data are expressed as mean ± S.E.M.
|
Results
|
|---|
Figure 2 illustrates a typical high-pressure liquid radiochromatogram of plasma from [14CH3]bPiDDB-treated rats after a 5.6 mg/kg s.c. dose. An authentic UV-absorbing standard of bPiDDB was introduced into the plasma sample. UV detection of the coinjected standard was performed at 260 nm, and 14C radioactivity in the sample was monitored by β-scintillation spectrometry. The UV-absorbing bPiDDB standard eluted at 5.6 min, and the 14C radioactivity in the sample was observed as a single peak that coeluted with the UV-absorbing bPiDDB standard. No other radiolabeled peaks were observed in the chromatogram. Analyses of 14C radioactivity in plasma samples obtained at 5, 10, 30, 60, 120, and 180 min after injection in rats that had received a dose of 5.6 mg/kg [14CH3]bPiDDB are shown in Fig. 3. In all cases, individual chromatograms showed the presence of only one radiolabeled peak, which coeluted with the UV-absorbing standard of bPiDDB. Recoveries of plasma 14C radiolabel in the column effluent for the 5.6 mg/kg s.c. dose were 98.3 ± 0.8% at 5 min, 98.6 ± 1.0% at 10 min, 98.9 ± 0.6% at 30 min, 99.1 ± 0.5% at 60 min, 99.8 ± 0.8% at 120 min, and 99.3 ± 0.3% at 180 min. For bPiDDB doses of 1 and 3 mg/kg s.c., the recovery of plasma 14C radiolabel in the HPLC column effluents ranged from 98.2 to 99.4% and from 98.3 to 99.5%, respectively, over a 180-min time course.
View larger version (31K):
[in this window]
[in a new window]
|
FIG. 3. HPLC chromatogram of plasma radioactivity at 5, 10, 30, and 60 min after a single s.c. dose of 5.6 mg/kg [14CH3]bPiDDB.
|
|
Pharmacokinetic Analysis. Figure 4 illustrates the mean ± S.E.M. plasma concentration-time profiles for bPiDDB after the i.v. dose and the three s.c. doses of bPiDDB. bPiDDB was rapidly absorbed and distributed to the vascular compartment within 1 min of administration and was detectable in plasma samples over a 1- to 180-min time period. Table 1 provides a summary of the mean ± S.E.M. values for the pharmacokinetic parameters for bPiDDB after s.c. administration. The absolute systemic bioavailabilities (F) of bPiDDB (1, 3, and 5.6 mg/kg s.c.) were obtained from eq. 4 by comparing the mean AUC after i.v. and s.c. injections and were 80.3, 68.2, and 103.7%, respectively. bPiDDB (1, 3, and 5.6 mg/kg) gave Cmax values of 0.13, 0.33, and 0.43 µg/ml, respectively, Tmax values of 5.0, 6.7, and 8.8 min, respectively, and t1/2 values of 76.0, 54.6, and 41.7 min, respectively. The plasma concentration-time curve (AUC0–) was selected as a pharmacokinetic index of drug exposure and reflects the total amount of drug absorbed by the body, irrespective of the rate of absorption. Mean AUC0– (micrograms per minute per milliliter) and mean Cmax (micrograms per milliliter) values for bPiDDB were dose-dependent (r2 = 0.9361 and 0.7968, respectively) over the 1 to 5.6 mg/kg dose range studied. Vss was 10.2 liters (30 l/kg) and CL was 0.6 to 0.9 l/h/kg over the dose range studied.
View larger version (27K):
[in this window]
[in a new window]
|
FIG. 4. Plasma concentration-time (AUC0–180) curves of bPiDDB in rats after i.v. (1 mg/kg) and s.c. administration (1, 3, and 5.6 mg/kg) of [14CH3]bPiDDB (n = 4–5). The curves in the inset represents AUC0–60 of bPiDDB in rats after i.v. (1 mg/kg) and s.c. administration (1, 3, and 5.6 mg/kg) of bPiDDB (n = 4–5). The analysis was carried out by β-scintillation spectrometry. All values show the mean ± S.E.M.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 1 Pharmacokinetic parameters of bPiDDB
Mean ± S.E.M. values for the pharmacokinetic parameters of bPiDDB after s.c. and i.v. administration (n = 3–5).
|
|
Brain Uptake Studies. In the brain uptake studies, HPLC analysis of both brain homogenates and matched plasma samples after s.c. injection of 5.6 mg/kg [14CH3]bPiDDB produced only one 14C-radiolabeled peak in the HPLC radiochromatogram, which was identified as bPiDDB from its coelution with a UV-absorbing authentic standard. As was observed in the plasma pharmacokinetic studies, percent recoveries of radiolabel from the chromatographic column eluents for both brain and matched plasma samples over a 60-min time course were close to 100% (Table 2). The plasma levels, brain levels, and brain/plasma ratios for the 5.6 mg/kg dose of bPiDDB over a 60-min time course are provided in Table 2. Although bPiDDB could be detected in plasma as early as 1 min after injection, no significant concentrations of bPiDDB were detected in brain at this time point. bPiDDB brain concentrations were in the range of 0.09 to 0.33 µg/g of brain tissue over the 60-min time course and were maximal at 10 min. Brain/blood ratios of 0.18 at 5 min to 0.51 at 60 min after injection were observed.
View this table:
[in this window]
[in a new window]
|
TABLE 2 Concentrations of bPiDDB in brain and plasma from bPiDDB-treated rats
Concentrations of bPiDDB in brain and plasma and brain/plasma ratios and percent recoveries of plasma and brain 14C in rat plasma and brain at time points of 1, 5, 10, 15, 20, and 60 min after administration of 5.6 mg/kg s.c.
|
|
Protein Binding. In the protein binding studies, 63 to 64% and 59 to 62% of bPiDDB was reversibly bound to rat plasma protein and brain protein, respectively, over the concentration range of 0.04 to 0.10 mg/ml (Fig. 5). Protein binding isotherms constructed over a wide range of bPiDDB concentrations (1–400 µg/ml) for both plasma and brain homogenate indicated that the observed protein binding was reversible in nature.
View larger version (20K):
[in this window]
[in a new window]
|
FIG. 5. Top, hyperbolic plot of 1:1 protein binding isotherm of [14CH3]bPiDDB in rat plasma. Results are mean ± S.E.M., n = 3. Bottom, hyperbolic plot of 1:1 protein binding isotherm of [14CH3]bPiDDB in rat brain supernatant. Results are mean ± S.E.M., n = 3.
|
|
|
Discussion
|
|---|
HPLC and radiometric analyses of plasma samples after s.c. administration indicated the absence of metabolites (60-min elution from the column) in plasma 5 to 180 min after [14CH3]bPiDDB (5.6 mg/kg s.c.) (Fig. 3), which is consistent with the high recovery of 14C radiolabel in the column effluent. Thus, bPiDDB behaves similarly to hexamethonium, a structurally related bis-quaternary ammonium drug, which is also poorly metabolized in rodents (Levine, 1960).
The plasma concentration-time profile for bPiDDB suggests two-compartment model behavior with a rapid distribution phase, followed by a slower elimination phase. bPiDDB was well absorbed within 1 min. Comparison of the profiles for all three s.c. doses indicates that absorption of bPiDDB was rapid and independent of dose. The extremely rapid time to reach peak plasma concentrations was unexpected, considering the high polarity and cationic nature of the molecule. After s.c. dosing, concentrations of bPiDDB in plasma declined rapidly over 12 to 20 min, suggesting a significant distribution phase, consistent with biexponential disappearance from plasma. The t1/2 was 42 to 76 min over the dosage range studied (1–5.6 mg/kg). Elimination phases after s.c. and i.v. dosing were comparable, suggesting that absorption is even more rapid than elimination. Once absorbed, clearance of bPiDDB from the systemic circulation was large (3.3–5.0 ml/min) and did not change significantly with increasing dose (Table 1). After s.c. administration of bPiDDB, most of the drug is rapidly absorbed and undergoes little, if any, presystemic elimination before it reaches the systemic circulation. In addition, the clearance (0.6–0.9 l/h/kg) is large, considering kidney and liver blood flow in rats (0.9 and 1.08 l/h/kg, respectively), suggesting that bPiDDB is efficiently removed by either the kidneys or the liver. Vss (10.2 liters or 30 l/kg) also suggests that bPiDDB undergoes significant distribution into tissues. Thus, bPiDDB appears to distribute and bind to tissue proteins in the extracellular space and/or extracellular fluid. Because bPiDDB is a polar, cationic molecule, it is somewhat surprising to observe such marked tissue distribution. HPLC and radiometric analyses indicated the absence of metabolites in plasma supernatant 5 to 180 min after bPiDDB (5.6 mg/kg s.c.) (Fig. 3). This lack of metabolism and the high F values result in direct systemic absorption of bPiDDB. Thus, the PK profile of bPiDDB (s.c.) shows rapid absorption and good bioavailability, affording adequate plasma concentrations for brain uptake possibly by facilitated transport.
In separate experiments, HPLC radiometric analysis of both brain homogenates and matched plasma samples from rats administered [14CH3]bPiDDB (5.6 mg/kg s.c.) showed only one 14C peak, identified as bPiDDB from coelution with a UV-absorbing authentic standard (Table 2). As was observed in the above plasma PK studies, 100% recoveries of 14C radiolabel from the HPLC column were obtained in these brain homogenate and matched plasma samples (Table 2), again indicating the absence of measurable amounts of 14C metabolites, both in plasma and in brain. Although bPiDDB was not detected in brain at 1 min after injection, it was detected in plasma at this time point. Both plasma and brain bPiDDB concentrations peaked at 10 min and were in the range of 0.16 to 0.89 µg/ml and 0.09 to 0.33 µg/g, respectively. In contrast, the brain/plasma ratio increased over the first 10 min after injection but did not significantly increase between 10 and 60 min after injection. Brain/plasma ratio values indicate that bPiDDB clearance from brain is slower than clearance from plasma. Although bPiDDB could be detected in plasma as early as 1 min after injection, a significant concentration of bPiDDB was only seen at 5 min after drug treatment. The data clearly indicate that bPiDDB enters the brain from the vasculature and may undergo sequestration in cells or extensive binding to brain tissues or simply be trapped in brain tissue. Because bPiDDB is a polar molecule, it should be easily cleared from plasma by excretion via the kidney. This may explain the slower clearance of bPiDDB from the brain compared with plasma. These results support the contention that the polar, cationic bPiDDB molecule enters brain by facilitated transport, because it is unlikely that passive transport plays a role in the transport of bPiDDB into the central nervous system. These results are also consistent with our recent findings that bPiDDB accesses brain after systemic administration via the saturable blood-brain barrier choline transporter (Allen et al., 2003; Lockman et al., 2005, 2008). We have also shown that after peripheral administration in rats, bPiDDB dose dependently reduces nicotine-induced increases in extracellular dopamine by selectively blocking nAChRs involved in regulating dopamine release (Rahman et al., 2007) and that bPiDDB selectively and dose-dependently decreases nicotine reinforcement in rats at s.c. doses of 1, 3, and 5.6 mg/kg (Neugebauer et al., 2006; M. T. Bardo, L. P. Dwoskin, and P. A. Crooks, unpublished results). A significant decrease in nicotine reinforcement was observed with 3 mg/kg s.c. bPiDDB at the 40–50-min time block in the rat behavioral study compared with saline; this result compares favorably with a t1/2 of 50 min for 3 mg/kg s.c. bPiDDB in the present study.
Because bPiDDB is not significantly metabolized in the rat, binding to plasma proteins and other tissue proteins may influence its PK profile. To determine the extent of binding of bPiDDB to plasma and brain supernatant protein, ultrafiltration studies were performed (Cheng et al., 2004). bPiDDB showed moderate plasma and brain supernatant protein binding (63–64 and 59–62%, respectively). In another series of experiments using [14CH3]bPiDDB, protein binding isotherms were generated for plasma and brain supernatant and bPiDDB binding was found to be fully reversible, as demonstrated by both plasma and brain supernatant isotherms intersecting at zero (Fig. 5).
In summary, the results from this study show that the novel nAChR bis-quaternary ammonium antagonist bPiDDB is distributed rapidly from the s.c. site of injection into plasma, affords good plasma concentrations, and probably accesses brain tissues via facilitated transport by the blood-brain barrier choline transporter to afford therapeutically relevant brain concentrations.
|
Footnotes
|
|---|
This research was supported by National Institutes of Health Grant U19 DA017548.
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
doi:10.1124/dmd.108.020354.
ABBREVIATIONS: nAChRs, nicotinic acetyl choline receptors; bPiDDB, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide; HPLC, high performance liquid chromatography; AUC, area under the curve; PK, pharmacokinetics.
Address correspondence to: Dr. Peter A. Crooks, George A. Digenis Professor in Drug, Design and Discovery, Department of Pharmaceutical Sciences, College of Pharmacy, Lexington, KY 40536-0082. E-mail: pcrooks{at}email.uky.edu
|
References
|
|---|
Allen DD, Lockman PR, Roder KE, Dwoskin LP, and Crooks PA (2003) Active transport of high-affinity choline and nicotine analogs into the central nervous system by the blood-brain barrier choline transporter. J Pharmacol Exp Ther 304: 1268–1274.[Abstract/Free Full Text]
Ayers JT, Dwoskin LP, Deaciuc AG, Grinevich VP, Zhu J, and Crooks PA (2002) bis-Azaaromatic quaternary ammonium analogues: ligands for 4β2* and 7* subtypes of neuronal nicotinic receptors. Bioorg Med Chem Lett 12: 3067–3071.[CrossRef][Medline]
Chen JC and Mannino DM (1999) Worldwide epidemiology of chronic obstructive pulmonary disease. Curr Opin Pulm Med 5: 93–99.[CrossRef][Medline]
Cheng Y, Ho E, Subramanyam B, and Tseng J-L (2004) Measurement of drug-protein binding by using immobilized human serum albumin liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 809: 67–73.[CrossRef][Medline]
Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, et al. (2005) Varenicline: an 4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48: 3474–3477.[CrossRef][Medline]
Dwoskin LP and Crooks PA (2001) Competitive neuronal nicotinic receptor antagonists: a new direction for drug discovery. J Pharmacol Exp Ther 298: 395–402.[Abstract/Free Full Text]
Dwoskin LP, Joyce BM, Zheng G, Neugebauer NM, Manda VK, Lockman P, Papke R, Bardo MT, and Crooks PA (2007) Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-picolinium)-12-triethylammonium-dodecane dibromide (TMPD). Biochem Pharmacol 74: 1271–1282.[CrossRef][Medline]
Dwoskin LP, Rauhut AS, King-Pospisil KA, and Bardo MT (2006) Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 12: 178–207.[CrossRef][Medline]
Dwoskin LP, Sumithran SP, Zhu J, Deaciuc AG, Ayers JT, and Crooks PA (2004) Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents. Bioorg Med Chem Lett 14: 1863–1867.[CrossRef][Medline]
Geldenhuys WJ, Lockman PR, Nguyen TH, Van der Schyf CJ, Crooks PA, Dwoskin LP, and Allen DD (2005) 3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter. Bioorg Med Chem 13: 4253–4261.[CrossRef][Medline]
Levine RR (1960) The physiological disposition of hexamethonium and related compounds. J Pharmacol Exp Ther 129: 296–304.[Abstract/Free Full Text]
Lockman PR, Manda VK, Geldenhuys WJ, Mittapalli RK, Thomas F, Albayati ZF, Crooks PA, Dwoskin LP, and Allen DD (2008) Carrier-mediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist, N,N'-dodecyl-bis-picolinium dibromide (bPiDDB) at the blood-brain barrier. J Pharmacol Exp Ther 324: 244–250.[Abstract/Free Full Text]
Lockman PR, Van der Schyf CJ, Abbruscato TJ, and Allen DD (2005) Chronic nicotine exposure alters blood-brain barrier permeability and diminishes brain uptake of methyllycaconitine. J Neurochem 94: 37–44.[CrossRef][Medline]
Lundahl LH, Henningfield JE, and Lukas SE (2000) Mecamylamine blockade of both positive and negative effects of IV nicotine in human volunteers. Pharmacol Biochem Behav 66: 637–643.[CrossRef][Medline]
Mannino DM and Braman S (2007) The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 4: 502–506.[Abstract/Free Full Text]
Mihalak KB, Carroll FI, and Leutje CW (2006) Varenicline is a partial agonist at 4β2 and full agonist at 7 neuronal nicotinic receptors. Mol Pharmacol 70: 801–805.[Abstract/Free Full Text]
Musick TJ, Gohdes M, Duffy A, Erickson DA, and Krieter PA (2008) Pharmacokinetics, disposition, and metabolism of bicifadine in the mouse, rat, and monkey. Drug Metab Dispos 36: 241–251.[Abstract/Free Full Text]
National Institutes of Health (1996) Guide for the Care and Use of Laboratory Animals. National Academy of Sciences, Washington, DC
Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, and Bardo MT (2006) Effect of a novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats. Psychopharmacology (Berl) 184: 426–434.[CrossRef][Medline]
Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, and Bardo MT (2007) The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens. Neuropharmacology 52: 755–763.[CrossRef][Medline]
Whittaker ET and Robinson G (1967) The Trapezoidal and Parabolic Rules. The Calculus of Observations: A Treatise on Numerical Mathematics, 4th ed. pp 156–158, Dover, New York.
Zheng G, Sumithran SP, Deaciuc AG, Dwoskin LP, and Crooks PA (2007) tris-Azaaromatic quaternary ammonium salts: novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg Med Chem Lett 17: 6701–6706.[Medline]
![[Feedback]](/icons/banner/feedbackACT.gif)
![[For Subscribers]](/icons/banner/subscriberACT.gif)
![[Archive]](/icons/banner/archiveACT.gif)
![[Search]](/icons/banner/searchACT.gif)
![[Contents]](/icons/banner/tocACT.gif)
Top
Abstract
Materials and Methods
